Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Pyxis Oncology Inc (PYXS)

77 + Investors. Track Smart Money conviction in PYXS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
35%

Smart Money Signals — PYXS

Based on 77 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their PYXS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 79% of 3.0Y peak

79% of all-time peak
77 funds currently hold this stock — 79% of the 3.0-year high of 98 funds (reached 2024 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 15% fewer funds vs a year ago

fund count last 6Q
14 fewer hedge funds hold PYXS compared to a year ago (-15% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🔴

Heavy selling pressure — only 35% buying

26 buying49 selling
Last quarter: 49 funds sold vs only 26 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
⚠️

Fewer new buyers each quarter (-8 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 16 → 14 → 22 → 14. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 29% medium ■ 25% new
36 out of 77 hedge funds have held PYXS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

14 → 16 → 14 → 22 → 14 new funds/Q
New funds entering each quarter: 16 → 14 → 22 → 14. A growing number of institutions are discovering PYXS each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Deep conviction — 52% of holders stayed 2+ years

■ 52% veterans ■ 26% 1-2yr ■ 21% new
Of 80 current holders: 42 (52%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
📋

Smaller funds dominant — 1% AUM from top-100

1% from top-100 AUM funds
24 of 77 holders rank in the top 100 by AUM, but together hold only 1% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.3
out of 10
Low Exit Risk
Exit risk score 3.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PYXS

In 2026 Q1, 26 hedge funds were net buyers of PYXS (14 opened a new position, 12 added to an existing one), while 49 reduced or exited (33 trimmed, 16 sold completely) — a 35% buyer ratio, indicating net institutional distribution. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 77.

Hedge Fund Ownership: PYXS

How many hedge funds hold PYXS — quarterly history vs. share price
Quarterly hedge fund ownership of PYXS vs. share price

Market Analysis: PYXS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PYXS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Pyxis Oncology Inc (PYXS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PYXS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
PYXS
+20.5%
XLV
+4.9%

PYXS outperformed XLV by +15.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
PYXS
-22.8%
XLV
+6.0%

Since the filing became public, PYXS outperformed XLV by -28.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

8 top-rated funds 2 high-conviction
Consensus
4.1
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: PYXS
77 + Investors

Track Smart Money conviction in PYXS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 77 79 -2.53%
13F Shares 28M 31M -9.12%
Total Value $601M $596M 0.88%
New Positions 14 22 -8
Increased Positions 11 28 -17
Closed Positions 16 17 -1
Reduced Positions 33 15 +18
Total Calls 3 2 50.0%
Total Puts 0 1 -100.0%
PUT/CALL Ratio 0.0 0.5 Bullish

Statistics: PYXS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

77 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PYXS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PYXS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 GordonMD Global Investments LP 4.19% 4,121,870 $6.0M
2 Pfizer Inc 3.86% 7,032,770 $9.2M
3 Laurion Capital Management LP 0.32% 4,997,333 $7.3M
4 Palo Alto Investors LP 0.23% 1,010,510 $1.5M
5 Decheng Capital LLC 0.07% 326,810 $477K
6 683 Capital Management, LLC 0.07% 896,263 $1.3M
7 Cable Car Capital, LP 0.03% 61,606 $90K
8 Longaeva Partners L.P. 0.03% 503,214 $735K
9 University of Chicago 0.02% 48,731 $71K
10 J. Derek Lewis & Associates Inc. 0.01% 53,000 $61K
11 Paces Ferry Wealth Advisors, LLC 0.01% 11,440 $17K
12 Maia Wealth LLC 0.01% 21,277 $31K
13 XTX Topco Ltd 0.01% 200,096 $292K
14 Catalyst Funds Management Pty Ltd 0.01% 20,400 $30K
15 Hager Investment Management Services, LLC 0.00% 5,000 $7K
16 Jacobs Levy Equity Management, Inc 0.00% 460,997 $673K
17 Bridgeway Capital Management, LLC 0.00% 81,260 $119K
18 Two Sigma Securities, LLC 0.00% 13,474 $20K
19 Renaissance Technologies LLC 0.00% 888,680 $1.3M
20 NewEdge Wealth, LLC 0.00% 116,006 $169K
21 China Universal Asset Management Co., Ltd. 0.00% 11,049 $16K
22 Graham Capital Management, L.P. 0.00% 22,748 $33K
23 Marshall Wace, LLP 0.00% 354,417 $517K
24 Tower Research Capital LLC (TRC) 0.00% 10,332 $15K
25 Panagora Asset Management Inc 0.00% 69,424 $101K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Pyxis Oncology Inc (PYXS)

What does the Smart Money Trend signal show for PYXS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their PYXS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for PYXS?

Heavy selling pressure — only 35% buying: Last quarter: 49 funds sold vs only 26 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for PYXS holders?

Smaller funds dominant — 1% AUM from top-100: 24 of 77 holders rank in the top 100 by AUM, but together hold only 1% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held PYXS?

47% of holders stayed for 2+ years: 36 out of 77 hedge funds have held PYXS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pyxis Oncology Inc (PYXS) following the 2026 Q1 hedge fund 13F filings?

As of today, PYXS has moved -22.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -28.8%. Since the quarter end (March 31, 2026), PYXS has gained +20.5% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →